South San Francisco, CA, Oct. 27, 2023– The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $42.1 million to fund various translational research — from treating brain cancers and salivary gland conditions to advancing a therapy for a rare metabolic disease. The goal of CIRM’s Translational program is … Continue reading CIRM invests more than $42 million in translational-stage research
Month: October 2023
FDA Accepts Application for CIRM-Funded Program Aimed to Treat Rare Pediatric Disease
The California Institute for Regenerative Medicine (CIRM) congratulates Rocket Pharmaceuticals, Inc, a leading late-stage biotechnology company. The company received U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel). CIRM helped support the development of this entiviral vector (LV)-based gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). What BLA … Continue reading FDA Accepts Application for CIRM-Funded Program Aimed to Treat Rare Pediatric Disease
CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC IrvineÂ
The California Institute for Regenerative Medicine (CIRM) Alpha Clinics network specializes in delivering stem and gene cell clinical trials to patients. The key to the network’s success is the ability to foster partnerships with patients, medical providers, and clinical trial sponsors. The CIRM Alpha Clinics Network consists of nine leading medical centers throughout California. Every … Continue reading CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC IrvineÂ
CIRM approves new plan to invest $110 million for neuropsychiatric disease research
The California Institute for Regenerative Medicine (CIRM) approved a new program called ReMIND at its September ICOC meeting. The program will award up to $110 million to advance basic research in neuropsychiatric diseases—one of California’s largest investments in this area. ReMIND (Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) aims to accelerate discoveries that improve … Continue reading CIRM approves new plan to invest $110 million for neuropsychiatric disease research